inbp20171127_8k.htm

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C. 20549

 

__________

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

 

November 27, 2017

 

__________

 

INTEGRATED BIOPHARMA, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

 

DELAWARE

(STATE OR OTHER JURISDICTION OF INCORPORATION)

 

 

001-31668 22-2407475

(COMMISSION FILE NUMBER)

(I.R.S. EMPLOYER IDENTIFICATION NO.)

 

225 Long Avenue

Hillsdale, New Jersey 07205

 (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

 

(973) 926-0816

(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On November 27, 2017, the Company held its 2017 Annual Meeting of Shareholders (the "Annual Meeting"). A total of 21,135,174 shares of the Company's common stock, par value $0.002 per share, were entitled to vote as of the close of business on October 18, 2017, the record date for the Annual Meeting. The holders of 17,562,780 shares of common stock, a majority, were present in person or represented by proxy at the Annual Meeting, at which the shareholders were asked to vote on two proposals. The proposals are described in detail in the Company’s definitive proxy materials which were filed with the Securities and Exchange Commission and first made available to shareholders on or about October 27, 2017. Set forth below is the matters acted upon by the Company’s shareholders at the Annual Meeting, and the final voting results of each such proposal.

 

Proposal No. 1 –To elect three Class II directors for a three year term to serve until the 2020 Annual Meeting of Stockholders

 

The Company’s shareholders voted for the election of the three Class II directors to serve until the 2020 Annual Meeting of Stockholders. The final voting results were as follows:

 

                   

Broker

  
   

For

    

Withheld

    

Non-Votes

  

Christina Kay

     13,249,664       265,823       4,047,293  

Robert Canarick

     13,249,614       265,873       4,047,293  

William H Milmoe

     13,245,408       270,079       4,047,293  

 

 

 

 

Proposal No. 2 – To ratify the appointment of the Company’s independent auditors for the fiscal year ending June 30, 2018

 

The Company’s shareholders voted in favor of ratifying the appointment of Friedman, LLP as the Company’s independent auditors for the fiscal year ending June 30, 2018. The final voting results were as follows:

 

For

    

Against

    

Abstain

  
17,272,385       85,930       204,465  

 

 

 

 

 

-2-
 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 27, 2017     INTEGRATED BIOPHARMA, INC.

 

By:     /s/ Dina L. Masi                    
Dina L. Masi
Chief Financial Officer

 

-3-